Barclays Maintains Overweight on Strategy, Lowers Price Target to $125

Benzinga Newsdesk www.benzinga.com Negative 84.2%

Neg 84.2% Neu 0% Pos 0%

Barclays analyst Nik Cremo maintains Strategy (NASDAQ:MSTR) with a Overweight and lowers the price target from $130 to $125.